Ilyang Pharmaceutical Co.,Ltd (KRX:007570)
South Korea
· Delayed Price · Currency is KRW 13,050
+10 (0.08%)
At close: Sep 10, 2025
KRX:007570 Revenue
Ilyang Pharmaceutical Co.,Ltd had revenue of 68.83B KRW in the quarter ending September 30, 2025, a decrease of -0.38%. This brings the company's revenue in the last twelve months to 276.09B, up 47.93% year-over-year. In the year 2024, Ilyang Pharmaceutical Co.,Ltd had annual revenue of 268.86B with 0.82% growth.
Revenue (ttm)
276.09B
Revenue Growth
+47.93%
P/S Ratio
0.85
Revenue / Employee
414.55M
Employees
666
Market Cap
233.92B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 268.86B | 2.19B | 0.82% |
| Dec 31, 2023 | 266.67B | 18.90B | 7.63% |
| Dec 31, 2022 | 247.77B | 5.26B | 2.17% |
| Dec 31, 2021 | 242.51B | -100.82B | -29.36% |
| Dec 31, 2020 | 343.33B | 18.76B | 5.78% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,504.84B |
| Celltrion | 3,895.99B |
| ALTEOGEN | 202.18B |
| ABL Bio | 88.44B |
| SK Biopharmaceuticals | 675.41B |
| Yuhan | 2,136.67B |
| LigaChem Biosciences | 159.27B |
| Peptron | 6.19B |